Natural Health Trends Corp. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; comparison is with Q1 2022. Unless noted otherwise, financial amounts below are in U.S. dollars and millions. The company sells NHT Global personal-care, wellness and quality-of-life products through direct selling and e-commerce.
Financial highlights
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Net sales | $11.861 million | $11.546 million |
| Gross profit / margin | $8.830 million / 74.5% | $8.638 million / 74.8% |
| Operating expenses | $9.224 million | $9.021 million |
| Operating loss | ($0.394 million) | ($0.383 million) |
| Other income, net | $0.681 million | $0.110 million |
| Net income (loss) | $0.257 million; $0.02 per diluted share | ($0.105 million); ($0.01) per diluted share |
| Operating cash flow | ($0.696 million) | ($2.348 million) |
- Sales increased 3%. Hong Kong sales rose 10% to $9.673 million, or 81.6% of total sales; substantially all Hong Kong sales came from products delivered to members in China. Sales outside Hong Kong declined 21%.
- Gross margin eased 0.3 percentage points. Commissions rose to 42.1% of sales from 41.0%, reflecting higher payouts and supplemental incentives; SG&A decreased to $4.232 million from $4.281 million.
- The company remained loss-making from operations. The move to net income primarily reflected higher interest income on cash equivalents, rather than improved operating profitability.
- Cash, cash equivalents and restricted cash were $66.648 million at quarter-end, down $3.098 million from year-end. Current assets were $75.012 million and current liabilities $20.025 million; reported working capital was $55.0 million and the current ratio was 3.7 to 1.
- No conventional borrowings are identified in the filing. Total liabilities were $32.132 million, including operating lease liabilities of $4.027 million and $12.1 million of repatriation-tax payable, of which $9.1 million was classified as noncurrent.
- Investing cash outflow was $0.007 million; financing cash outflow was $2.304 million, consisting of quarterly dividends of $0.20 per share. The company paid a $0.20 dividend in Q1 and declared another after quarter-end. A further $21.9 million remained under its share repurchase authorization.
Material changes and management commentary
- Sales improvement in Hong Kong was attributed to the relaxation of COVID-19 controls in China and Hong Kong and fewer supply-chain and distribution disruptions than in Q1 2022. Management resumed in-person events in China and planned additional events.
- Management attributed weaker sales outside Hong Kong partly to a slowdown in Japan amid tighter industry regulation and to geopolitical conditions affecting Russia and Peru.
- Active members declined to 38,330 from 44,490 a year earlier, although they were slightly below the 38,660 reported at December 31, 2022. An active member is defined as one who ordered at least once in the preceding year.
- Operating cash use narrowed year over year, primarily because of lower commission and employee-related payouts. Management said existing liquidity and operating cash flows should fund normal operations and commitments for the foreseeable future.
Outlook, risks and other matters
- No specific numerical earnings or revenue guidance is provided. Management expects near-term financial performance to remain adversely affected.
- The business is highly concentrated in Hong Kong-linked sales to China and is exposed to member attrition, direct-selling and product regulation, foreign exchange, geopolitical conditions, and economic and political developments in Hong Kong and China. The company does not currently hold a direct-selling license in China; timing and prospects for reapplying or obtaining one are uncertain.
- Management said China’s business environment remains challenging, including from regulatory scrutiny and negative sentiment toward health-product companies. The durability and business impact of relaxed COVID-19 restrictions remain uncertain.
- The filing identifies risks involving product and market concentration, third-party manufacturers and logistics providers, member conduct, product acceptance, and legal and regulatory compliance. It reports no material change to the risk factors in the 2022 Form 10-K.
- The company reported no legal proceedings in this filing and no material changes in internal control over financial reporting; management concluded disclosure controls were effective at March 31, 2023.
- Other notable items: $4.1 million of cash was held in Chinese bank accounts subject to foreign-currency controls; $55.2 million of cash equivalents consisted of available-for-sale investments. The filing reports no material impact from adopting the expected-credit-loss accounting standard.
Important facts for investors to verify
- Whether Hong Kong sales tied to China and the active-member base stabilize or continue to weaken.
- Whether operations can return to profitability and generate positive operating cash flow, given the ongoing operating loss and continued dividend payments.
- The source and sustainability of non-operating income, particularly interest earned on cash equivalents.
- Developments in China-related licensing, regulatory conditions, logistics, and the potential accessibility of cash subject to currency controls.
- The status and payment schedule of the repatriation-tax liability, lease obligations, and any future dividend or repurchase decisions.